Navigation Links
CryoCath Appoints New Chief Financial Officer
Date:2/26/2008

Toronto Stock Exchange Symbol: CYT

http://www.cryocath.com

MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that Chief Financial Officer, L. Derek Lindsay, will be leaving the Company on April 4, 2008. Effective April 7, 2008, Ginette Gagne will take over the role of Chief Financial Officer at CryoCath. Mr. Lindsay has agreed to stay on in the role of Chief Financial Officer to ensure a smooth transition.

"Since joining CryoCath, Derek has been actively involved in significant change and we thank him for his contributions to the Company's development and wish him well for the future," said Jan Keltjens, President and Chief Executive Officer of CryoCath. "I am very pleased to announce the appointment of Ginette Gagne to the position of Chief Financial Officer at CryoCath. Her extensive experience building and running world-class financial organizations, combined with her hands-on experience in the global medical device business, will support CryoCath in achieving our ambitious growth strategy."

Over the past 19 years, Ginette has developed an impressive career track record through leadership positions in various corporations with progressive senior roles and responsibilities. She joins CryoCath from Boston Scientific Corporation, where she most recently served as Vice President Finance of Europe. In this capacity, she was responsible for managing a team of more than 150 people in 30 countries and played a key role in transitioning their business from a highly centralized model to a country focused model. Before this assignment she was the Vice President, Finance of Boston Scientific Inter Continental. Prior to her eight years with Boston Scientific, Ginette held financial leadership roles at Fisher Scientific International, Fisher France OSI S.A. and Fisher Scientific Canada. She began her career with Northern Telecom Ltd.

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath Technologies notice of annual meeting
2. CryoCath Announces Fiscal 2008 First Quarter Results
3. CryoCath Provides Update on Patent Infringement Lawsuit
4. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath announces 2007 fourth quarter and fiscal year end financial results
7. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
8. CryoCath to present at CIBC Healthcare Conference
9. CryoCath files patent infringement lawsuit
10. Ceremed Appoints Vice President for Sales and Business Development
11. ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 ... ... call on elected representatives in state legislatures and Congress to protect parental rights ... the public health and safety in America. , The demonstration coincides with a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar 29, 2017 Research ... Global Market - Forecast to 2023" report to their offering. ... The ablation ... CAGR to reach $20,995.5 million by 2023. Ablation ... wide range of purposes, from cancerous or diseased tissue removal, to ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: